TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics”, reports that its Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting participants. The study is evaluating the participants experience wearing…


Previous articleTryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida
Next articlePurchasing & Accounting Analyst